The use of methadone for cancer pain

Carla Ripamonti, Mauro Bianchi

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Methadone is not a new analgesic drug [69]. Several studies have demonstrated that methadone is a valid alternative to morphine, hydromorphone, and fentanyl for the treatment of cancer-related pain, and extensive reviews on the subject have been published in recent years [10,23,25,64,70,71]. Most people involved in pain therapy, however, are not well informed about the properties of methadone. The authors believe that the low cost of methadone paradoxically contributes to the limited knowledge of its characteristics and to the restricted therapeutic use of this drug. The low cost of methadone means there is little financial incentive for pharmaceutical companies to invest in research or to disseminate scientific information. Unfortunately, the lack of scientific information from pharmaceutical companies frequently results in a lack of knowledge on the part of physicians. Unless the existing approach changes, both culturally and politically, ignorance about methadone will persist among medical experts. The low cost of methadone, rather than being an advantage, will result in the limited exploitation of an effective drug.

Original languageEnglish
Pages (from-to)543-555
Number of pages13
JournalHematology/Oncology Clinics of North America
Volume16
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

Methadone
Costs and Cost Analysis
Pharmaceutical Preparations
Hydromorphone
Fentanyl
Therapeutic Uses
Cancer Pain
Morphine
Analgesics
Motivation
Physicians
Pain
Therapeutics
Research

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

The use of methadone for cancer pain. / Ripamonti, Carla; Bianchi, Mauro.

In: Hematology/Oncology Clinics of North America, Vol. 16, No. 3, 2002, p. 543-555.

Research output: Contribution to journalArticle

Ripamonti, Carla ; Bianchi, Mauro. / The use of methadone for cancer pain. In: Hematology/Oncology Clinics of North America. 2002 ; Vol. 16, No. 3. pp. 543-555.
@article{9a3c7c7c1a2b4f0bb123c29e8894cb69,
title = "The use of methadone for cancer pain",
abstract = "Methadone is not a new analgesic drug [69]. Several studies have demonstrated that methadone is a valid alternative to morphine, hydromorphone, and fentanyl for the treatment of cancer-related pain, and extensive reviews on the subject have been published in recent years [10,23,25,64,70,71]. Most people involved in pain therapy, however, are not well informed about the properties of methadone. The authors believe that the low cost of methadone paradoxically contributes to the limited knowledge of its characteristics and to the restricted therapeutic use of this drug. The low cost of methadone means there is little financial incentive for pharmaceutical companies to invest in research or to disseminate scientific information. Unfortunately, the lack of scientific information from pharmaceutical companies frequently results in a lack of knowledge on the part of physicians. Unless the existing approach changes, both culturally and politically, ignorance about methadone will persist among medical experts. The low cost of methadone, rather than being an advantage, will result in the limited exploitation of an effective drug.",
author = "Carla Ripamonti and Mauro Bianchi",
year = "2002",
doi = "10.1016/S0889-8588(02)00017-5",
language = "English",
volume = "16",
pages = "543--555",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - The use of methadone for cancer pain

AU - Ripamonti, Carla

AU - Bianchi, Mauro

PY - 2002

Y1 - 2002

N2 - Methadone is not a new analgesic drug [69]. Several studies have demonstrated that methadone is a valid alternative to morphine, hydromorphone, and fentanyl for the treatment of cancer-related pain, and extensive reviews on the subject have been published in recent years [10,23,25,64,70,71]. Most people involved in pain therapy, however, are not well informed about the properties of methadone. The authors believe that the low cost of methadone paradoxically contributes to the limited knowledge of its characteristics and to the restricted therapeutic use of this drug. The low cost of methadone means there is little financial incentive for pharmaceutical companies to invest in research or to disseminate scientific information. Unfortunately, the lack of scientific information from pharmaceutical companies frequently results in a lack of knowledge on the part of physicians. Unless the existing approach changes, both culturally and politically, ignorance about methadone will persist among medical experts. The low cost of methadone, rather than being an advantage, will result in the limited exploitation of an effective drug.

AB - Methadone is not a new analgesic drug [69]. Several studies have demonstrated that methadone is a valid alternative to morphine, hydromorphone, and fentanyl for the treatment of cancer-related pain, and extensive reviews on the subject have been published in recent years [10,23,25,64,70,71]. Most people involved in pain therapy, however, are not well informed about the properties of methadone. The authors believe that the low cost of methadone paradoxically contributes to the limited knowledge of its characteristics and to the restricted therapeutic use of this drug. The low cost of methadone means there is little financial incentive for pharmaceutical companies to invest in research or to disseminate scientific information. Unfortunately, the lack of scientific information from pharmaceutical companies frequently results in a lack of knowledge on the part of physicians. Unless the existing approach changes, both culturally and politically, ignorance about methadone will persist among medical experts. The low cost of methadone, rather than being an advantage, will result in the limited exploitation of an effective drug.

UR - http://www.scopus.com/inward/record.url?scp=0036021425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036021425&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(02)00017-5

DO - 10.1016/S0889-8588(02)00017-5

M3 - Article

VL - 16

SP - 543

EP - 555

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 3

ER -